<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="6acc9f96-7088-45a7-b48f-1a861e3467ab" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-692c62f7-0bc8-4d1d-9827-e15b2a6f6db6" mediaType="text/x-hl7-title+xml">Lactated Ringer&#8217;s and 5% Dextrose
        Injection, USP<br />in VIAFLEX Plastic Container</title>
<effectiveTime value="20060524" />
<setId root="6acc9f96-7088-45a7-b48f-1a861e3467ab" />
<versionNumber value="2" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Baxter Healthcare Corporation</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="89DF693D-6C83-0A0A-DF75-14B523CFD2C6" />
<effectiveTime value="20060524" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0125" codeSystem="2.16.840.1.113883.6.69" />
<name>Lactated Ringers and Dextrose</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="5">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="5" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="IY9XDZ35W2" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Dextrose</name>
<activeMoiety>
<activeMoiety>
<code code="IY9XDZ35W2" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>dextrose</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="600">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="600" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="310">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="310" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Lactate</name>
<activeMoiety>
<activeMoiety>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium lactate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="30">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="30" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="20">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="20" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Calcium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Calcium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Sodium chloride, sodium lactate, potassium chloride, calcium chloride and dextrose</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0125-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator unit="mL" value="1000">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0125-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-f6ad0baa-8523-477c-bcde-6ae75cd9e5b1">
<id root="3FF36513-D722-CB5B-6702-8E0CB6CBFF4E" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-76d943de-1403-4fa4-8c30-528c8d9fccda" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-8bf41b21-da9a-44bc-a291-5b1284300e9f"><paragraph ID="INV-f5801fe2-1491-439f-8f4b-67eb3dbe4b94">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution for
                            fluid and electrolyte replenishment and caloric supply in a single dose
                            container for intravenous administration. Each 100 mL contains 5 g
                            Dextrose Hydrous, USP*; 600 mg Sodium Chloride, USP (NaCl); 310 mg
                            Sodium Lactate (C3H5NaO3); 30 mg of Potassium Chloride, USP (KCl); and
                            20 mg Calcium Chloride, USP (CaCl2 &#183; 2H20). It contains no antimicrobial
                            agents. </paragraph><paragraph ID="INV-41ffbd3b-070c-486e-86ae-9b62f514aff2">Approximate pH 5.0
                            (4.0 to 6.5).</paragraph><renderMultiMedia referencedObject="MM-17b23e9e-7eb9-4c42-ad54-431253d3f24e" /><paragraph ID="INV-ef18dad9-d671-4d9c-a0f5-50f2954b1e95">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP administered intravenously has value as a
                            source of water, electrolytes, and calories. One liter has an ionic
                            concentration of 130 mEq sodium, 4 mEq potassium, 2.7 mEq calcium, 109
                            mEq chloride and 28 mEq lactate. The osmolarity is 525 mOsmol/L (calc).
                            Normal physiologic range is approximately 280 to 310 mOsmol/L.
                            Administration of substantially hypertonic solutions may cause vein
                            damage. The caloric content is 180 kcal/L.</paragraph><paragraph ID="INV-f3bf4da1-dc8b-438a-b7ee-28b1755a1a8f">The VIAFLEX plastic
                            container is fabricated from a specially formulated polyvinyl chloride
                            (PL 146 Plastic). The amount of water that can permeate from inside the
                            container into the overwrap is insufficient to affect the solution
                            significantly. Solutions in contact with the plastic container can leach
                            out certain of its chemical components in very small amounts within the
                            expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
                            per million. However, the safety of the plastic has been confirmed in
                            tests in animals according to USP biological tests for plastic
                            containers as well as by tissue culture toxicity studies.</paragraph></text>
<effectiveTime value="20060524" />
<component>
<observationMedia ID="MM-17b23e9e-7eb9-4c42-ad54-431253d3f24e">
<value mediaType="image/gif"><reference value="Lactated-Ringers-and-5-Dextrose-Injection.JPG" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-0cdcb4ea-e7ec-4f8b-af0e-1234a81658d9">
<id root="3199CB60-4FB1-13D9-707F-48063EEA22FB" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-72596f74-08c7-4749-a0ce-2c6c971446d5" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-8bdba2c4-16bc-421d-befd-abe6de567354"><paragraph ID="INV-7a1aa658-103f-46a9-9125-13e5b8d76965">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP has value as a source of water,
                            electrolytes, and calories. It is capable of inducing diuresis depending                 on the clinical condition of the patient.</paragraph><paragraph ID="INV-d02c654e-0ea6-44eb-8169-0ff22a7f3223">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP produces a metabolic alkalinizing effect.
                            Lactate ions are metabolized ultimately to carbon dioxide and water,
                            which requires the consumption of hydrogen cations.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-69bdbdb6-8184-4449-a8c1-233f1b39fa33">
<id root="C2372778-2EEF-992A-1E59-A7C8215BDE74" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-99de773b-51f8-4c11-abe0-39e75347f182" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-d580c253-991d-4c07-9a3c-8038f981536e"><paragraph ID="INV-8e991fd3-3f61-410b-9651-d118572028ef">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP is indicated as a source of water,
                            electrolytes and calories or as an alkalinizing agent.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-655d9347-cd51-4e8a-bed0-a93e47fd74ae">
<id root="01AA4729-CCE7-53EB-F91A-A97638F42481" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-a7ebfd8b-cc19-4f84-a759-257d52287cc8" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-ed318ada-6d13-41c3-8e07-5a49432c40ef"><paragraph ID="INV-5aa8fdd0-774d-4f74-a1c8-ef400d796bf1">Solutions
                            containing dextrose may be contraindicated in patients with known
                            allergy to corn or corn products.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-f7c20012-b33c-4db4-a0da-358656e19870">
<id root="2DC3C9AD-EA98-4305-C41E-480206A250F4" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-fa744f2b-440b-4889-ad0e-08ae98bf5056" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-c651c422-55c5-4b11-a8db-0b360b6607ff"><paragraph ID="INV-628abbc4-38e1-4e35-a9d7-9107831e325c">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP should be used with great care, if at
                            all, in patients with congestive heart failure, severe renal
                            insufficiency, and in clinical states in which there exists edema with
                            sodium retention.</paragraph><paragraph ID="INV-bc421218-cc56-4b81-80af-938efb1c0bfc">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP should be used with great care, if at
                            all, in patients with hyperkalemia, severe renal failure, and in
                            conditions in which potassium retention is present.</paragraph><paragraph ID="INV-0038f4cc-561b-44ce-8b4a-88682040b83c">Lactated Ringer&#8217;s                    and 5% Dextrose Injection, USP should be used with great care in
                            patients with metabolic or respiratory alkalosis. The administration of
                            lactate ions should be done with great care in those conditions in which
                            there is an increased level or an impaired utilization of these ions,
                            such as severe hepatic insufficiency.</paragraph><paragraph ID="INV-a45f817d-ad29-4417-bc7f-d8c357d962d9">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP should not be administered simultaneously                     with blood through the same administration set because of the likelihood
                            of coagulation.</paragraph><paragraph ID="INV-86491914-a2b1-43d2-953c-775a9df34fc7">The intravenous
                            administration of Lactated Ringer&#8217;s and 5% Dextrose Injection, USP can
                            cause fluid and/or solute overloading resulting in dilution of serum
                            electrolyte concentrations, overhydration, congested states, or
                            pulmonary edema. The risk of dilutional states is inversely proportional
                            to the electrolyte concentrations of the injection. The risk of solute
                            overload causing congested states with peripheral and pulmonary edema is
                            directly proportional to the electrolyte concentrations of the
                            injection.</paragraph><paragraph ID="INV-7dc80632-5845-4d1c-8ede-6bd8add8d052">In patients with
                            diminished renal function, administration of Lactated Ringer&#8217;s and 5%
                            Dextrose Injection, USP may result in sodium or potassium retention.</paragraph><paragraph ID="INV-40d6b4e4-4146-424d-a259-575b05c1072b">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP is not for use in the treatment of lactic
                            acidosis.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-232e7fe0-9b83-475a-a3c6-57274e53f5cb">
<id root="F95446ED-0246-DE30-7DCF-F7157E640C2D" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-b3a8dd3d-5608-4048-a7d0-fa9889bd81e6" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text ID="INV-cdead9c7-df4d-4851-b7e6-982e7d063d1c"><paragraph ID="INV-1f8fa32f-2e40-4d09-97c8-dbcf8195b786">Clinical evaluation
                            and periodic laboratory determinations are necessary to monitor changes
                            in fluid balance, electrolyte concentrations, and acid base balance
                            during prolonged parenteral therapy or whenever the condition of the
                            patient warrants such evaluation.</paragraph><paragraph ID="INV-0c2899f7-b265-41ec-81c2-17b27b6821a5">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP should be used with caution. Excess
                            administration may result in metabolic alkalosis.</paragraph><paragraph ID="INV-29b6c001-7b91-44d1-94f7-392a72ea6efa">Caution must be
                            exercised in the administration of Lactated Ringer&#8217;s and 5% Dextrose
                            Injection, USP to patients receiving corticosteroids or corticotropin.</paragraph><paragraph ID="INV-6c2099e1-47df-4f91-80d0-e55d5f3badfa">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP should be used with caution in patients                     with overt or subclinical diabetes mellitus.</paragraph></text>
<effectiveTime value="20060524" />
<component>
<section ID="INV-72b969de-0147-4000-a362-b93d425e72be">
<id root="47B7E2DE-594D-5034-A2D4-C2D990D4D506" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-ca24db3e-49fc-4a40-a2d6-99bf60f9b5b9" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060524" />
<component>
<section ID="INV-0086cc0f-e5c1-43e0-a9f0-09e00f59c582">
<id root="68E82BC3-A8A0-57DB-197D-82BF046894A1" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-5d1084ef-f22d-40ac-b3f1-318f66c5db29" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<effectiveTime value="20060524" />
<component>
<section>
<id root="C63D1745-281B-442B-0C69-F5F212473571" />
<title ID="INV-7f13499c-9c6e-4ea3-83e2-676929a8186e" mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text ID="INV-03073554-ecb6-40c9-ab4e-406fbcf68ba5"><paragraph ID="INV-647e9aed-2b07-4375-b80e-95ee2159c831">Animal reproduction studies have not been
                                                  conducted with Lactated Ringer&#8217;s and 5% Dextrose
                                                  Injection, USP. It is also not known whether
                                                  Lactated Ringer&#8217;s and 5% Dextrose Injection, USP
                                                  can cause fetal harm when administered to a
                                                  pregnant woman or can affect reproduction
                                                  capacity. Lactated Ringer&#8217;s and 5% Dextrose
                                                  Injection, USP should be given to a pregnant
                                                  woman only if clearly needed.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-efde87c2-051b-49da-b764-6d517c960e14">
<id root="7B09E16B-32CB-9270-37B5-990B37001047" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-2f52d982-b750-4fe7-af69-bbc656dc065f" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-d234abaa-b96c-4480-90cb-671fbda0e9b4"><paragraph ID="INV-1c48713f-639f-4520-b859-9185b3dfe264">Safety and
                                    effectiveness of Lactated Ringer&#8217;s and 5% Dextrose Injection,
                                    USP in pediatric patients have not been established by adequate
                                    and well controlled trials, however, the use of lactated
                                    ringer&#8217;s and dextrose solutions in the pediatric population is
                                    referenced in the medical literature. The warnings, precautions
                                    and adverse reactions identified in the label copy should be
                                    observed in the pediatric population.</paragraph><paragraph ID="INV-2bc4a12f-09d2-4ae2-9998-671bda8cef76">In very low
                                    birth weight infants, excessive or rapid administration of
                                    dextrose injection may result in increased serum osmolality and
                                    possible hemorrhage.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-efc0cef8-3c17-43d4-93c9-771d62ad69f8">
<id root="B0939DD9-9326-3CD3-0EBD-53F46001A2AB" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS                                 AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-ee76ff12-049b-4e91-9296-6f0807145ab9" mediaType="text/x-hl7-title+xml">Carcinogenesis,
                                mutagenesis, impairment of fertility</title>
<text ID="INV-5bc29d35-00ba-4505-9cfa-8291eab8dbbc"><paragraph ID="INV-89088cb3-be04-4e1f-a866-f19c8b0612e9">Studies
                                    with Lactated Ringer&#8217;s and 5% Dextrose Injection, USP have not
                                    been performed to evaluate carcinogenic potential, mutagenic           potential, or effects on fertility.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-3f8184ba-be06-4c36-b37e-b66deb94abdd">
<id root="79A6E3A5-2A69-10F6-E0BC-74361089AB0D" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-8bfa0078-f857-4728-8b99-7c0d967d9b2d" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-479ea62d-75e8-428b-a7b4-26d8eb2ad9c5"><paragraph ID="INV-289d7043-ffb5-428a-88d2-6eec1f1d8360">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when Lactated Ringer&#8217;s and 5% Dextrose Injection, USP is
                                    administered to a nursing mother.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-33c7d3f7-1472-437b-bff9-f5f5b1696330">
<id root="CCE827A8-C170-0C9C-973E-B392472269C0" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-030b3905-0cca-4717-b62b-332e3a661a70" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-1bd19040-783f-4f5e-ac2f-f9708d7aaca8"><paragraph ID="INV-a4338791-5a59-4bfc-b9b2-4a2051868b4e">Clinical
                                    studies of Lactated Ringer&#8217;s and 5% Dextrose Injection, USP did
                                    not include sufficient numbers of subjects aged 65 and over to                                determine whether they respond differently from younger
                                    subjects. Other reported clinical experience has not identified              differences in responses between the elderly and younger
                                    patients. In general, dose selection for an elderly patient
                                    should be cautious, usually starting at the low end of the
                                    dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or drug therapy.</paragraph><paragraph ID="INV-e1270d4d-f5ce-4fff-84c3-962b2de9cc5a">Do not
                                    administer unless solution is clear and the seal is
                                intact.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-52a3f828-1dcd-4296-bc96-85c70d94b0f1">
<id root="D4086850-519D-D898-64BD-719110AA2D43" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-d88b0130-44e3-4d7c-92f9-84fba8c0ad70" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-573d36e3-34e5-4046-97e1-92d8cf582c4e"><paragraph ID="INV-f3892de1-69ce-4610-ac59-e22e98b3542f">Allergic reactions
                            or anaphylactoid symptoms such as localized or generalized urticaria and
                            pruritus; periorbital, facial, and/or laryngeal edema, coughing,
                            sneezing, and/or difficulty with breathing have been reported during
                            administration of Lactated Ringer&#8217;s and 5% Dextrose Injection, USP. The
                            reporting frequency of these signs and symptoms is higher in women             during pregnancy.</paragraph><paragraph ID="INV-6636636d-5115-4774-815c-daa3e16f7d0d">Reactions which may          occur because of the solution or the technique of administration include
                            febrile response, infection at the site of injection, venous thrombosis
                            or phlebitis extending from the site of injection, extravasation, and
                            hypervolemia.</paragraph><paragraph ID="INV-3df908ca-467b-48c0-b177-6ff6452fb280">If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures, and save the
                            remainder of the fluid for examination if deemed necessary.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-c364f022-8681-4940-b666-02cf47a8c19c">
<id root="F877493A-FE62-A902-ACC5-D513388AB1CF" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-bc06af9c-deb2-4496-a727-52ea90193260" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-5c5eea12-5c89-4a3d-a988-438cd759759e"><paragraph ID="INV-80428b37-68a8-4dcc-9ccc-0de2b1e87222">As directed by a
                            physician. Dosage is dependent upon the age, weight and clinical
                            condition of the patient as well as laboratory determinations.</paragraph><paragraph ID="INV-722100aa-59b4-440c-aa12-9dc21689b2d9">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit.</paragraph><paragraph ID="INV-b558b65b-444f-4b3c-b06e-5869beae9e5e">All injections in   VIAFLEX plastic containers are intended for intravenous administration
                            using sterile equipment.</paragraph><paragraph ID="INV-615cca12-ec74-445a-a7ab-800efbb3d453">As reported in the
                            literature, the dosage and constant infusion rate of intravenous
                            dextrose must be selected with caution in pediatric patients,
                            particularly neonates and low weight infants, because of the increased
                            risk of hyperglycemia/hypoglycemia.</paragraph><paragraph ID="INV-58a1ed6b-51f9-451e-b031-7434445d98c8">Additives may be
                            incompatible. Complete information is not available. Those additives
                            known to be incompatible should not be used. Consult with pharmacist, if
                            available. If, in the informed judgement of the physician, it is deemed
                            advisable to introduce additives, use aseptic technique. Mix thoroughly
                            when additives have been introduced. Do not store solutions containing
                            additives.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-4b821b7f-3688-4b43-9f46-119667e44886">
<id root="DB6DD6C1-BAED-9F41-32F6-B41C7F5BB5AE" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-abcc74a5-6145-4094-806e-22a013c413ed" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-f7f02a71-03a5-42cd-9f04-5acc01f5e2e6"><paragraph ID="INV-059b0b71-a21d-49ec-901f-4cfc85ad58da">Lactated Ringer&#8217;s
                            and 5% Dextrose Injection, USP in VIAFLEX plastic containers is
                            available as follows:</paragraph><table frame="void"><col align="left" width="75pt" />
<col align="left" width="75pt" />
<col align="left" width="125pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle"><content styleCode="underline bold">Code</content></td><td align="left" valign="middle"><content styleCode="underline bold">Size</content></td><td align="left" valign="middle"><content styleCode="underline bold">NDC</content></td></tr>
<tr valign="top"><td align="left" valign="middle">
                                        2B2073 </td><td align="left" valign="middle">
                                        500 mL </td><td align="left" valign="middle"> NDC
                                        0338-0125-03 </td></tr>
<tr valign="top"><td align="left" valign="middle"> 2B2074 </td><td align="left" valign="middle"> 1000 mL </td><td align="left" valign="middle"> NDC 0338-0125-04 </td></tr>
</tbody>
</table><paragraph ID="INV-5ae960f4-e458-41c4-b950-37e3f097a88c">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. It is recommended the product be stored at room temperature
                            (25&#176;C); brief exposure up to 40&#176;C does not adversely affect the
                        product.</paragraph></text>
<effectiveTime value="20060524" />
<component>
<section ID="INV-74bb3b32-723c-4735-b590-41b1004c36ea">
<id root="DCB78DD4-C9A2-8F7C-1583-CBF14BB51569" />
<code code="38056-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SUPPLEMENTAL PATIENT MATERIAL" />
<title ID="INV-dae06b01-1f13-4d27-b68d-d856040e434d" mediaType="text/x-hl7-title+xml">Directions for use
                                of VIAFLEX plastic container</title>
<text ID="INV-7b6b3165-e4cb-4491-8661-640cccff97b0"><paragraph ID="INV-f19c168c-60b0-4b37-a71e-e8c30d508e66"><content styleCode="bold">WARNING:</content> Do not use plastic
                                    containers in series connections. Such use could result in air
                                    embolism due to residual air being drawn from the primary
                                    container before administration of the fluid from the secondary
                                    container is completed. </paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-4f2fafcc-f2b2-47f5-90c2-f2207f2bec4e">
<id root="3B569B3E-32D5-9FF4-D997-2FD8B727A0EA" />
<title ID="INV-aab74d8f-cdb5-47be-8b05-308a5475148c" mediaType="text/x-hl7-title+xml">To Open </title>
<text ID="INV-e63f38a4-9e9c-4737-9cfb-e3ab714a97af"><paragraph ID="INV-582ee866-208c-4816-a621-023b7a55ca53">Tear
                                    overwrap down side at slit and remove solution container. Some
                                    opacity of the plastic due to moisture absorption during the
                                    sterilization process may be observed. This is normal and does
                                    not affect the solution quality or safety. The opacity will
                                    diminish gradually. Check for minute leaks by squeezing inner
                                    bag firmly. If leaks are found, discard solution as sterility
                                    may be impaired. If supplemental medication is desired, follow
                                    directions below.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-2743978d-58c8-4abb-af6a-76fac29fe216">
<id root="9EC924E7-CBD1-905C-8BE7-613A0F01CA4E" />
<title ID="INV-9ab9cfa8-2e8f-4a50-8b59-b9d3987aea27" mediaType="text/x-hl7-title+xml">Preparation for                    Administration</title>
<text ID="INV-28d7a9e0-7dfd-460d-93ad-158b2cb34839"><paragraph ID="INV-5da1e4b1-4899-432e-832e-1fd46e3884d7">1. Suspend
                                    container from eyelet support. </paragraph><paragraph ID="INV-4b0a2c7f-06d0-4cc6-91f4-ea97e62e4b53">2. Remove
                                    plastic protector from outlet port at bottom of container. </paragraph><paragraph ID="INV-aec6554d-7b91-42bc-8506-84274e55db11">3. Attach
                                    administration set. Refer to complete directions accompanying
                                    set</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-575304db-a969-4728-90b1-73dcc128c37c">
<id root="65FE0729-DDA8-4B8B-C422-AA994CF332C0" />
<title ID="INV-f05cf5c3-622a-4d25-bb4e-8098cc578b43" mediaType="text/x-hl7-title+xml">To Add Medication</title>
<text ID="INV-0a6389a8-4bd5-4409-95ba-50452e6d5057"><paragraph ID="INV-0a3a26db-e064-4600-a386-ec1df4d5bd7c"><content styleCode="bold">Warning:</content> Additives may be
                                    incompatible.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-616439ed-fdee-463c-b4ac-0de5c7988d4a">
<id root="87C67274-639A-F500-B0AD-E0889C60B291" />
<title ID="INV-8635ae25-d64f-4de2-a894-28e073205ce9" mediaType="text/x-hl7-title+xml">To add medication
                                before solution administration</title>
<text ID="INV-f8654b86-ab72-43f8-aeb0-eeedbfec4d87"><paragraph ID="INV-bd222db7-8bcf-45f7-8a8f-1470af6a7c3f">1. Prepare
                                    medication site. </paragraph><paragraph ID="INV-c4b768e9-cae2-4d5b-9433-6bcb8a5996cc">2. Using
                                    syringe with 19 to 22 gauge needle, puncture medication port and
                                    inject. </paragraph><paragraph ID="INV-4521fb79-6565-4698-9e29-566eaba4121d">3. Mixsolution and medication thoroughly. For high density medication
                                    such as potassium chloride, squeeze ports while ports are
                                    upright and mix thoroughly.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
<component>
<section ID="INV-072b5814-b00a-4cde-a8b0-5ba3e0726828">
<id root="F7CA05F4-93F6-B9AB-0B37-AFC8C2D96663" />
<title ID="INV-e84a97a9-1c89-4e13-a087-9daec5bce3df" mediaType="text/x-hl7-title+xml">To add medication
                                during solution administration</title>
<text ID="INV-4cf530f8-a134-4460-8888-940bd26bd4e3"><paragraph ID="INV-9a4ea572-a2f9-4282-b8eb-ce28db9e2d4e">1. Close
                                    clamp on the set. </paragraph><paragraph ID="INV-e9f4c95c-a524-46e7-80b4-6ba0f10a40aa">2. Prepare
                                    medication site. </paragraph><paragraph ID="INV-9dc0e3fc-b594-4d8a-b5fa-6f9fc6bdd551">3. Using
                                    syringe with 19 to 22 gauge needle, puncture resealable
                                    medication port and inject. </paragraph><paragraph ID="INV-4770124b-2663-40b8-a9ad-0f8cda501dfb">4. Remove
                                    container from IV pole and/or turn to an upright position. </paragraph><paragraph ID="INV-9da0bc69-e4ec-4f7b-bda6-d3890c7988d6">5. Evacuate
                                    both ports by squeezing them while container is in the upright
                                    position. </paragraph><paragraph ID="INV-d5226926-e24a-49dd-90a7-a9ddc7a62bfc">6. Mix
                                    solution and medication thoroughly. </paragraph><paragraph ID="INV-1e810ae3-25ab-4f5a-b16b-d4ca150e3785">7. Return
                                    container to in use position and continue administration.</paragraph><paragraph ID="INV-0c41d860-ddd3-4676-aad4-4e1c7a3278a3"><content styleCode="bold">Baxter Healthcare Corporation</content></paragraph><paragraph ID="INV-19484f28-b6ab-4d91-ab3f-407bae658088">Deerfield,
                                    IL 60015 USA</paragraph><paragraph ID="INV-264155a8-50c8-415d-bc19-903207ce8253">Printed in
                                    USA</paragraph><paragraph ID="INV-0bd128c7-2d73-449c-b02f-99abaeeaed51">Baxter,
                                    VIAFLEX, and PL 146 are trademarks of Baxter International
                                Inc.</paragraph></text>
<effectiveTime value="20060524" />
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
